Robert Berahovich

Title: Innovations by Robert Berahovich

Introduction

Robert Berahovich is an accomplished inventor based in Berkeley, CA, known for his significant contributions to the field of immunology. He holds two patents that focus on enhancing immune responses and understanding chemokine-mediated inflammation. His work has implications for vaccine development and therapeutic applications.

Latest Patents

Berahovich's latest patents include compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof. The inventors discovered that a CKβ8-1 truncation variant, CKβ8-1 (25-116), acts as a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). This discovery is crucial as it highlights the role of CKβ8-1(25-116) in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. Additionally, he identified an alternatively spliced exon of CKβ8-1, named SHAAGtide, which is functional on both monocytes and neutrophils expressing FPRL1. His work provides compositions and methods for inducing or enhancing immune responses, particularly in vaccine formulations for therapeutic and prophylactic use.

Career Highlights

Berahovich is currently associated with Chemocentryx, Inc., where he continues to innovate in the field of immunology. His research has led to advancements in understanding how truncated chemokines can activate CCR1 and/or FPRL1, providing methods for identifying agents that modulate these activities. His contributions are vital for developing new therapeutic strategies.

Collaborations

Some of his notable coworkers include Zhenhua Miao and Brett Anthony Premack, who collaborate with him on various research projects.

Conclusion

Robert Berahovich's work exemplifies the intersection of innovation and practical application in immunology. His patents and research continue to pave the way for advancements in vaccine development and immune response enhancement.